Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistance"

American Heart Journal

Volumn 158, Issue 6, 2009, Pages 925-932

  Serebruany, Victor ^a   Cherala, Ganesh ^b   Williams, Craig ^b   Surigin, Serge ^a   Booze, Christopher ^a   Kuliczkowski, Wiktor ^c   Atar, Dan ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DRUG METABOLITE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DRUG METABOLISM; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SURVIVOR; THROMBOCYTE AGGREGATION INHIBITION;

AGED; BLOOD PLATELETS; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STROKE; TICLOPIDINE;

EID: 70549107994     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.10.012     Document Type: Article

References (35)

1. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348 (1996) 1329-1339
2. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 345 (2001) 494-502
3. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
4. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
5. Sacco R.L., Diener H.C., Yusuf S., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 359 (2008) 1238-1251
6. Healey J.S., Hart R.G., Pogue J., et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W). Stroke 39 (2008) 1482-1486
7. Serebruany V.L. Aggressive antiplatelet strategies: time to reconsider. Eur Heart J 28 (2007) 2183-2184
8. Chew D.P., Bhatt D.L., Sapp S., et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 (2001) 201-206
9. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
10. Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154 (2007 Aug) 221-231
11. Gori A.M., Marcucci R., Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52 (2008) 734-739
12. Wenaweser P., Dörffler-Melly J., Imboden K., et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
13. Pereillo J.M., Maftouh M., Andrieu A., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30 (2002) 1288-1295
14. Taubert D., Kastrati A., Harlfinger S., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92 (2004) 311-316
15. Patel N.K., Subbaiah G., Shah H., et al. Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma. J Chromatogr Sci 46 (2008) 867-875
16. Ruggeri Z.M. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hemat 31 (1994) 229-239
17. Serebruany V.L., Oshrine B.R., Malinin A.I., et al. Noncompliance in clinical trials. Am Heart J 150 (2005) 882-886
18. The FDA Prasugrel Secondary Review. Available at:. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-00-FDA.htm
19. Angiolillo D.J., Suryadevara S., Capranzano P., et al. Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother. 9 (2008) 2893-2900
20. Serebruany V.L. Prasugrel and cancer risks: potential causes and implications. Am J Med 122 (2009) 407-408
21. Serebruany V.L., Hanley D.F., Atar D., et al. Non-compliance in antiplatelet trials: the AGATE trial perspective. Stroke 35 (2004) 143
22. Cuisset T., Frere C., Quilici J., et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 157 (2009) 889-893
23. Gencheva E., Sloan M., Leurgans S., et al. Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology 23 (2004) 61-66
24. Topol E.J., Easton D.J., Harrington R.A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108 (2003) 299-406
25. Newby L.K., Bhapkar M.V., White H.D., et al. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis 16 (2003) 119-128
26. Hamann G.F., Weimar C., Glahn J., et al. Adherence to secondary stroke prevention strategies-results from the German Stroke Data Bank. Cerebrovasc Dis. 15 (2003) 282-288
27. Roy P., Bonello L., Torguson R., et al. Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol 103 (2009) 801-805
28. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
29. Pallares M.J., Powers E.R., Zwerner P.L., et al. Barriers to clopidogrel adherence following placement of drug-eluting stents. Ann Pharmacother 43 (2009) 259-267
30. Sørensen R., Gislason G.H., Fosbøl E.L., et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 66 (2008) 875-884
31. Vikman S., Airaksinen K.E., Tierala I., et al. Improved adherence to practice guidelines yields better outcome in high-risk patients with acute coronary syndrome without ST elevation: findings from nationwide FINACS studies. J Intern Med 256 (2004) 316-323
32. von Beckerath N., Taubert D., Pogatsa-Murray G., et al. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 93 (2005) 789-791
33. von Beckerath N., Taubert D., Pogatsa-Murray G., et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
34. Liberopoulos E.N., Florentin M., Mikhailidis D.P., et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 7 (2008) 717-725
35. Ho P.M., Peterson E.D., Wang L., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299 (2008) 532-539